Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

This study is testing the combination of vismodegib (a targeted drug that blocks a cell growth pathway called Hedgehog) plus atezolizumab (an immunotherapy drug) for women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer. Platinum resistance means the cancer stopped responding to standard platinum-based chemotherapy within 6 months, making it very hard to treat. **You may be eligible if:** - You have confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer - Your cancer progressed during or within 6 months of completing platinum-based chemotherapy - You have measurable or evaluable disease on scans - Your general health is adequate (ECOG score 0–2) **You may NOT be eligible if:** - Your cancer has not been platinum-resistant - You have uncontrolled autoimmune disease - You have had severe allergic reactions to similar immunotherapy drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.